Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Anthony Olszanski

Email
Center AffiliationsMolecular Therapeutics

Publications (37) (print view)

no pagination
Boland PM, Meyer JE, Berger AC, Cohen SJ, Neuman T, Cooper HS, Olszanski AJ, Davey M, Cheng JD, Lebenthal A, Burtness BA, Scott WJ, Astsaturov IA. Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection. Am J Clin Oncol. 2017 Aug;40(4):393-8.   PMCID: PMC5026539
Boyle SM, Ali N, Olszanski AJ, Park DJ, Xiao G, Guy S, Doyle AM. Donor-Derived Metastatic Melanoma and Checkpoint Inhibition. Transplantation proceedings. 2017 Sep;49(7):1551-4.
Hussaini A, Olszanski AJ, Stein CA, Bosch B, Nemeth P. Impact of an alternative steroid on the relative bioavailability and bioequivalence of a novel versus the originator formulation of abiraterone acetate. Cancer Chemother Pharmacol. 2017 Jul 10;80(3):479-86.   PMCID: PMC5573754
Infante JR, Patnaik A, Verschraegen CF, Olszanski AJ, Shaheen M, Burris HA, Tolcher AW, Papadopoulos KP, Beeram M, Hynes SM, Leohr J, Lin AB, Li LQ, McGlothlin A, Farrington DL, Westin EH, Cohen RB. Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer. Cancer Chemother Pharmacol. 2017 Feb;79(2):315-26.
Infante JR, Patnaik A, Verschraegen CF, Olszanski AJ, Shaheen M, Burris HA, Tolcher AW, Papadopoulos KP, Beeram M, Hynes SM, Leohr J, Lin AB, Li LQ, McGlothlin A, Farrington DL, Westin EH, Cohen RB. Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer. Cancer Chemother Pharmacol. 2017 Jan 17;.
Papadopoulos KP, Gluck L, Martin LP, Olszanski AJ, Tolcher AW, Ngarmchamnanrith G, Rasmussen E, Amore B, Nagorsen D, Hill JS, Stephenson J. First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients With Advanced Solid Tumors. Clin Cancer Res. 2017 Oct;23(19):5703-10.
Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RH, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, Kirkwood JM, Gajewski TF, Chen L, Gorski KS, Anderson AA, Diede SJ, Lassman ME, Gansert J, Hodi FS, Long GV. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2017 Sep 07;170(6):1109-1119e10.
Boland PM, Meyer JE, Berger AC, Cohen SJ, Neuman T, Cooper HS, Olszanski AJ, Davey M, Cheng JD, Lebenthal A, Burtness BA, Scott WJ, Astsaturov IA. Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection. Am J Clin Oncol. 2016 Mar 16;.   PMCID: PMC5026539
Coit DG, Thompson JA, Algazi A, Andtbacka R, Bichakjian CK, Carson WE, Daniels GA, DiMaio D, Fields RC, Fleming MD, Gastman B, Gonzalez R, Guild V, Johnson D, Joseph RW, Lange JR, Martini MC, Materin MA, Olszanski AJ, Ott P, Gupta AP, Ross MI, Salama AK, Skitzki J, Swetter SM, Tanabe KK, Torres-Roca JF, Trisal V, Urist MM, McMillian N, Engh A. NCCN Guidelines Insights: Melanoma, Version 3.2016. J Natl Compr Canc Netw. 2016 Aug;14(8):945-58.
Coit DG, Thompson JA, Algazi A, Andtbacka R, Bichakjian CK, Carson WE, Daniels GA, DiMaio D, Ernstoff M, Fields RC, Fleming MD, Gonzalez R, Guild V, Halpern AC, Hodi FS, Joseph RW, Lange JR, Martini MC, Materin MA, Olszanski AJ, Ross MI, Salama AK, Skitzki J, Sosman J, Swetter SM, Tanabe KK, Torres-Roca JF, Trisal V, Urist MM, McMillian N, Engh A. Melanoma, version 2.2016 clinical practice guidelines in oncology. JNCCN Journal of the National Comprehensive Cancer Network. 2016 Jan;14(4):450-73.
Kelly KR, Gabrail N, Weitman S, Sarantopoulos J, Olszanski AJ, Edenfield W, Venitz J, Reddy G, Yang A, Hasal SJ, Lockhart AC. Phase 1 study evaluating the safety and pharmacokinetics of pralatrexate in relapsed/refractory advanced solid tumors and lymphoma patients with mild, moderate, and severe renal impairment. Cancer Chemother Pharmacol. 2016 Nov;78(5):929-39.
Olszanski AJ, Smith DC, Camacho LH, Thompson J, Ramalingam SS, Harvey RD, Campos L, Ferry D, Tang S, Gao L, Safran H. Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors. The oncologist. 2016 Mar 16;21(4):402-3.   PMCID: PMC4828123
Zibelman M, Pollak N, Olszanski AJ. Autoimmune inner ear disease in a melanoma patient treated with pembrolizumab. Journal for immunotherapy of cancer. 2016 Feb;4:8.   PMCID: PMC4754989
Zijoo R, Olszanski AJ, Weinberg DS. Biomarkers and stage II colorectal cancer therapy. Translational Cancer Research. 2016 Jun;5:S84-S86.   PMCID: Editorial
Faivre SJ, Olszanski AJ, Weigang-Kohler K, Riess H, Cohen RB, Wang X, Myrand SP, Wickremsinhe ER, Horn CL, Ouyang H, Callies S, Benhadji KA, Raymond E. Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors. Invest New Drugs. 2015 Dec;33(6):1206-16.
Kurzrock R, Colevas AD, Olszanski A, Akerley W, Arteaga CL, Carson WE, Clark JW, DiPersio JF, Ettinger DS, Morgan RJ, Schwartzberg LS, Venook AP, Gocke CD, Tait J, Stewart FM. NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys. J Natl Compr Canc Netw. 2015 Nov;13(11):1337-46.
Olszanski AJ. Principles of immunotherapy. J Natl Compr Canc Netw. 2015 May;13(5 Suppl):670-2.
Rixe O, Puzanov I, LoRusso PM, Cohen RB, Morris JC, Olowokure OO, Yin JY, Doroumian S, Shen L, Olszanski AJ. Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies. Anti-Cancer Drugs. 2015 Aug;26(7):785-92.   PMCID: 4484664
Zibelman M, Wong YN, Devarajan K, Malizzia L, Corrigan A, Olszanski AJ, Denlinger CS, Roethke SK, Tetzlaff CH, Plimack ER. Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors. Invest New Drugs. 2015 Oct;33(5):1040-7.   PMCID: 4573837
Coit DG, Thompson JA, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daniels GA, Daud A, DiMaio D, Fleming MD, Gonzalez R, Guild V, Halpern AC, Hodi S, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Martini MC, Olszanski AJ, Ross MI, Salama A, Swetter SM, Tanabe KK, Trisal V, Urist MM, McMillian NR, Ho M. Melanoma, Version 4.2014 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network. 2014 May;12(5):621-9.   PMCID: No NIH funding
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

Anthony Olszanski Sparkline Graph

Graph Interactions

Co-Authors:

Similar Investigators:


Keywords (MeSH):


Last updated on Thursday, November 02, 2017